Cargando…

Single intravitreal ranibizumab for myopic choroidal neovascularization

We report a case of myopic choroidal neovascularization that showed improvement after a single injection of ranibizumab. A 45-year-old Chinese man with high myopia presented with sudden onset painless central scotoma of his right eye of 2 weeks’ duration. There was no history of trauma. His right ey...

Descripción completa

Detalles Bibliográficos
Autores principales: Nor-Masniwati, Saidin, Shatriah, Ismail, Zunaina, Embong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155273/
https://www.ncbi.nlm.nih.gov/pubmed/21847340
http://dx.doi.org/10.2147/OPTH.S21057
_version_ 1782210101278408704
author Nor-Masniwati, Saidin
Shatriah, Ismail
Zunaina, Embong
author_facet Nor-Masniwati, Saidin
Shatriah, Ismail
Zunaina, Embong
author_sort Nor-Masniwati, Saidin
collection PubMed
description We report a case of myopic choroidal neovascularization that showed improvement after a single injection of ranibizumab. A 45-year-old Chinese man with high myopia presented with sudden onset painless central scotoma of his right eye of 2 weeks’ duration. There was no history of trauma. His right eye vision on presentation was 6/30 which showed no improvement with pinhole. The right fundus showed myopic maculopathy at the posterior pole with subretinal hemorrhage at the inferotemporal fovea. The optic disc was tilted with inferotemporal peripapillary atrophy. There was a myopic maculopathy appearance in the macula of the left eye. Fundus fluorescein angiography revealed choroidal neovascularization at the fovea of the right eye. A diagnosis of right eye choroidal neovascularization secondary to myopic maculopathy was made. A single intravitreal injection of ranibizumab 0.05 mL was given. Ten weeks following intravitreal injection, vision had improved to 6/7.5, and repeated fundus fluorescein angiography showed absence of choroidal neovascularization. Follow-up at 6 months showed visual acuity had normalized to 6/6 with glasses, which was maintained up to 12 months following treatment. The right fundus showed no further subretinal hemorrhage with no new lesions.
format Online
Article
Text
id pubmed-3155273
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-31552732011-08-16 Single intravitreal ranibizumab for myopic choroidal neovascularization Nor-Masniwati, Saidin Shatriah, Ismail Zunaina, Embong Clin Ophthalmol Case Report We report a case of myopic choroidal neovascularization that showed improvement after a single injection of ranibizumab. A 45-year-old Chinese man with high myopia presented with sudden onset painless central scotoma of his right eye of 2 weeks’ duration. There was no history of trauma. His right eye vision on presentation was 6/30 which showed no improvement with pinhole. The right fundus showed myopic maculopathy at the posterior pole with subretinal hemorrhage at the inferotemporal fovea. The optic disc was tilted with inferotemporal peripapillary atrophy. There was a myopic maculopathy appearance in the macula of the left eye. Fundus fluorescein angiography revealed choroidal neovascularization at the fovea of the right eye. A diagnosis of right eye choroidal neovascularization secondary to myopic maculopathy was made. A single intravitreal injection of ranibizumab 0.05 mL was given. Ten weeks following intravitreal injection, vision had improved to 6/7.5, and repeated fundus fluorescein angiography showed absence of choroidal neovascularization. Follow-up at 6 months showed visual acuity had normalized to 6/6 with glasses, which was maintained up to 12 months following treatment. The right fundus showed no further subretinal hemorrhage with no new lesions. Dove Medical Press 2011 2011-04-08 /pmc/articles/PMC3155273/ /pubmed/21847340 http://dx.doi.org/10.2147/OPTH.S21057 Text en © 2011 Nor-Masniwati et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Case Report
Nor-Masniwati, Saidin
Shatriah, Ismail
Zunaina, Embong
Single intravitreal ranibizumab for myopic choroidal neovascularization
title Single intravitreal ranibizumab for myopic choroidal neovascularization
title_full Single intravitreal ranibizumab for myopic choroidal neovascularization
title_fullStr Single intravitreal ranibizumab for myopic choroidal neovascularization
title_full_unstemmed Single intravitreal ranibizumab for myopic choroidal neovascularization
title_short Single intravitreal ranibizumab for myopic choroidal neovascularization
title_sort single intravitreal ranibizumab for myopic choroidal neovascularization
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3155273/
https://www.ncbi.nlm.nih.gov/pubmed/21847340
http://dx.doi.org/10.2147/OPTH.S21057
work_keys_str_mv AT normasniwatisaidin singleintravitrealranibizumabformyopicchoroidalneovascularization
AT shatriahismail singleintravitrealranibizumabformyopicchoroidalneovascularization
AT zunainaembong singleintravitrealranibizumabformyopicchoroidalneovascularization